ImmunityBio (IBRX) Cash from Investing Activities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash from Investing Activities data on file, last reported at -$31.6 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$31.6 million, down 866.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$185.6 million (down 774.71% YoY), and the FY2025 annual result was -$149.8 million, down 1123.26% from the prior year.
• Cash from Investing Activities slipped to -$31.6 million in Q1 2026 per IBRX's latest filing, from $43.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $116.7 million in Q2 2022 and troughed at -$181.4 million in Q3 2025.
• A 5-year average of -$11.6 million and a median of -$8.6 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 1012.33% in 2022, then tumbled 1238.27% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$18.9 million in 2022, then soared by 111.9% to $2.2 million in 2023, then soared by 337.26% to $9.8 million in 2024, then jumped by 343.09% to $43.6 million in 2025, then tumbled by 172.64% to -$31.6 million in 2026.
• Business Quant data shows IBRX's Cash from Investing Activities at -$31.6 million in Q1 2026, $43.6 million in Q4 2025, and -$181.4 million in Q3 2025.